Capecitabine in locally advanced anal cancer, do we need randomised evidence?

References

• Oliveira SC, Moniz CM, Riechelmann R, et al. Phase II study of capecitabine in substitution of 5FU in the chemoradiotherapy regimen for patients with localized squamous cell carcinoma of the anal canal. J Gastrointest Cancer. 2016;47:75–81.
   PubMedGoogle Scholar
• Uronis HE, Bendell JC. Anal cancer: an overview. Oncologist. 2007;12:524–534.
   PubMed Web of Science ®Google Scholar
• Ryan DP, Compton C, et al. Carcinoma of the anal canal. New England. Journal of Medicine. 2000;342:792–800.
   Google Scholar
• Nigro ND, Seydel HG, Considine B, et al. Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. Cancer. 1983;51:1826–1829.
   PubMed Web of Science ®Google Scholar
• Meulendijks D, Dewit L, Tomasoa NB, et al. Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative option. Br J Cancer. 2014;111:1726–1733.
   PubMed Web of Science ®Google Scholar
• UK Co-ordinating Committee on Cancer Research. Epidermoid anal cancer: results from the UKCCR randomized trial of radiotherapy alone versus radiotherapy, 5 fluorouracil and mitomycin. UKCCR anal cancer trial working party. The Lancet. 1996;348(9034):1049–1054.
   PubMed Web of Science ®Google Scholar
• Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncology. 1997 May;15(5):2040–2049.
   PubMed Web of Science ®Google Scholar
• Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncology. 1996 Sept;14(9):2527–2539.
   PubMed Web of Science ®Google Scholar
• Sischy B, Doggett RL, Krall JM, et al. Definitive irradiation and chemotherapy for radiosensitization in management of anal carcinoma: interim report on Radiation Therapy Oncology Group study no. 8314. J Natl Cancer Institute. 1989;81:850–856.
   PubMed Web of Science ®Google Scholar
• Roh M, Yothers GA, O’Connell MJ, et al. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. J Clin Oncology. 2011;29(18 Suppl):3503.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced eosophagogastric cancer. New England J Med. 2008;358:36–46.
   PubMed Web of Science ®Google Scholar
• Schuller J, Cassidy J, et al. Preferential activation of capecitabine in tumour following oral administration in colorectal cancer patients. Cancer Chemother Pharmacol. 2000;45:291–297.
   PubMed Web of Science ®Google Scholar
• Lawrence TS, Blackstock AW, et al. The mechanism of action of radiosensitization of concentional chemotherapeutic agents. Semin Radiation Oncology. 2003 Jan;13(1):13–21.
   PubMed Web of Science ®Google Scholar
• Eviq Cancer Treatment Online, https://www.eviq.org.au/Category/tabid/65/categoryid/372/Default.aspx
   Google Scholar
• Chu E, Schulman KL, Zelt S, et al. Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancer. Cancer. 2009;115:1412–1423.
   PubMed Web of Science ®Google Scholar
• Jansman FG, Postma MJ, Van Hartskamp D, et al. Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands. Clin Ther. 2004;26:579–589.
   PubMed Web of Science ®Google Scholar
• James R, Wan S, Glynne-Jones R, et al. A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus. J Clin Oncology (Proc ASCO). 2009;27(18S(partII of II)):797s[abstract LBA-4009].
   Google Scholar
• Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin and radiotherapy vs fluorouracil, cisplatin and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008;199:1914–1921.
   Web of Science ®Google Scholar
• Conroy T, Ducreux M, Lemanski C, et al. Treatment intensification by induction chemotherapy (ICT) and radiation dose escalation in locally advanced squamous anal canal carcinoma (LAAC): definitive analysis of the intergroup ACCORD-03 trial. J Clinical Oncology. 2009;27(15s (Part I of II)):176s [abstract 4033].
   PubMed Web of Science ®Google Scholar
• Glynne-Jones R, Meadows H, Wan S, et al. EXTRA – a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer. Int J Radiation Oncology Biol Phys. 2008;72(1):119–126.
   PubMed Web of Science ®Google Scholar
• Deenen M, Dewit L, Boot H, et al. Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase I study. Int J Radiation Oncol Biol Phys. 2013;85(5): e201–e207.
   Google Scholar
• Thind G, Johal B, Follwell M, et al. Chemoradiation with capecitabine and mitomycin C for stage I-III anal squamous cell carcinoma. Radiation Oncology. 2014;9:124.
   PubMed Web of Science ®Google Scholar
• Peixoto RD, Wan DD, Schellenberg D, et al. A comparison between 5-fluorouracil/mitomycin and capecitabine/mitomycin in combination with radiation for anal cancer. J Gastrointestinal Oncology. 2016 Aug;7(4):665–672.
   PubMed Web of Science ®Google Scholar
• Bradford RH, Zafar SY. Capecitabine in the management of colorectal cancer. Cancer Management Res. 2011;3:79–89.
   Google Scholar
• Sawada N, Ishikawa T, Sekiguchi F, et al. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Research. 1990 Oct;5(10):2948–2953.
   Google Scholar
• Hofheinz RD, Wenz F, Post S, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomized multicenter, non inferiority, phase 3 trial. Lancet Oncol. 2012 June;13(6):579–588.
   PubMed Web of Science ®Google Scholar
• Kang J, Demaria S, Formenti S. Current clinical trials testing the combination of immunotherapy with radiotherapy. J Immunotherapy Cancer. 2016 Sep 20;4:51.
   PubMed Web of Science ®Google Scholar